CPMS ID: 59444 IRAS ID: 1009041
To determine the clinical effectiveness, safety and cost-effectiveness of budesonide-formoterol reliever therapy either alone or as part of maintenance and reliever therapy (MART) compared with SABA, reliever therapy, either used as monotherapy or with the child’s usual maintenance treatment (prescribed within licence), in children with asthma aged ≥ 6 to <12 years.
Updated 19/06/2025
Inclusion Criteria
Clinician diagnosis of asthma
2. Children aged ≥ 6 to <12 years
3. Washout period of 6 months post previous IMP studies
4. Prescribed asthma medication, (within license) in past 6 months (SABA (salbutamol) with or without ICS or ICS+LABA)
5. Parent or carer able to understand the
Exclusion Criteria
Other chronic airways disease including but not limited to bronchiectasis, cystic fibrosis, sickle cell disease
2. Children prescribed non-salbutamol SABA (e.g. terbutaline) as their reliever
3. Already using ICS-formoterol as a reliever
4. Children on step 5, very high dose treatment (e.g. high dose ICS/LABA, prescription of biological therapy such as omalizumab)
5. Any known or suspected contraindications to the medications prescribed in the study or their respective excipients
Disclaimer:
Please note the resources provided are designed to assist with the identification of potentially suitable patients and to appropriately code these patient if required.
These resources have been developed based on the criteria provided by the relevant study team and whilst every effort has been made to make them universally implementable they rely on read codes and the data stored in the individual practice's clinical system. These resources are intended to assist with identification but should be used in conjunction with clinical oversight and a clear understanding of the study parameters.
While we endeavour to keep the information, tools and resources provided up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the tools provided for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of the tools provided.